Savant Capital LLC Lowers Stake in Organon & Co. (NYSE:OGN)

Savant Capital LLC reduced its stake in shares of Organon & Co. (NYSE:OGN) by 83.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 18,017 shares of the company’s stock after selling 88,315 shares during the quarter. Savant Capital LLC’s holdings in Organon & Co. were worth $269,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Prospera Private Wealth LLC purchased a new stake in shares of Organon & Co. during the third quarter valued at $25,000. Horizon Bancorp Inc. IN grew its holdings in Organon & Co. by 2,401.5% during the 4th quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock worth $25,000 after acquiring an additional 1,585 shares in the last quarter. Versant Capital Management Inc grew its holdings in Organon & Co. by 92.2% during the 4th quarter. Versant Capital Management Inc now owns 2,760 shares of the company’s stock worth $41,000 after acquiring an additional 1,324 shares in the last quarter. MassMutual Private Wealth & Trust FSB grew its holdings in Organon & Co. by 32.4% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company’s stock worth $41,000 after acquiring an additional 672 shares in the last quarter. Finally, Abich Financial Wealth Management LLC grew its holdings in Organon & Co. by 5,646.3% during the 3rd quarter. Abich Financial Wealth Management LLC now owns 2,356 shares of the company’s stock worth $45,000 after acquiring an additional 2,315 shares in the last quarter. 77.43% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on OGN shares. Barclays dropped their target price on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. Finally, Morgan Stanley dropped their target price on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating on the stock in a report on Friday, February 14th. One analyst has rated the stock with a sell rating, three have issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $20.80.

Organon & Co. Stock Up 1.1 %

NYSE:OGN opened at $15.46 on Wednesday. Organon & Co. has a fifty-two week low of $13.87 and a fifty-two week high of $23.10. The stock has a market capitalization of $3.98 billion, a P/E ratio of 3.07, a P/E/G ratio of 0.83 and a beta of 0.76. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. The company’s 50-day simple moving average is $15.36 and its 200-day simple moving average is $17.34.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings data on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.09). The company had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. On average, equities analysts anticipate that Organon & Co. will post 3.82 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 13th. Investors of record on Monday, February 24th will be given a $0.28 dividend. This represents a $1.12 annualized dividend and a dividend yield of 7.25%. The ex-dividend date of this dividend is Monday, February 24th. Organon & Co.’s payout ratio is currently 22.22%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.